| Name | Title | Contact Details |
|---|
The Denver Public Library (DPL) is a public library system serving the city of Denver, Colorado. Established in 1889, it has grown into a vital community resource with 27 locations throughout the city. The library offers a wide range of services, including early literacy programs for children, digital access with computer training, and various community programs such as workshops and cultural events. DPL provides access to a vast collection of materials, including books, audiobooks, e-books, and DVDs. It also offers digital resources like databases and online courses. The library features special collections, including the Western History and Genealogy Department and the Blair-Caldwell African American Research Library. Its mission is to create welcoming spaces for exploration and connection, emphasizing values such as curiosity, equity, and community engagement.
We at Kerkman & Dunn are dedicated to our clients, we will fight for you. Contact us at 414-278-7000 or fill out our online contact form today.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
MedVet is the leading veterinarian owned and led network of specialty and emergency hospitals dedicated to delivering exceptional care and a deeply supportive experience to pets and their loving families, referring veterinarians, and team members. For more than 35 years, MedVets empathetic, insightful, and driven team of expert caregivers has helped the organization grow to be the preferred choice for high quality, compassionate care, proudly serving more than 500,000 patients each year in communities throughout the United States. Our caregivers are deeply committed to MedVets mission of Leading Specialty Healthcare for Pets and our driven by our core values of Teamwork, Leadership, and Compassion. Visit www.medvet.com for further information and to view employment opportunities at MedVet. MedVet is an Equal Opportunity Employer.